{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T07:06:19Z","timestamp":1789110379389,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Capital Medical University Xuanwu Hospital","award":["LCYJ202419"],"award-info":[{"award-number":["LCYJ202419"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"DOI":"10.1007\/s41669-026-00681-8","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T06:23:06Z","timestamp":1789107786000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Threshold Price of Belantamab for Relapsed\/Refractory Multiple Myeloma in China: A Cost-Effectiveness Analysis"],"prefix":"10.1007","author":[{"given":"Xiaotong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxuan","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhizhou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5286-4623","authenticated-orcid":false,"given":"Xianzhe","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"issue":"12","key":"681_CR1","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","volume":"21","author":"SK Kumar","year":"2024","unstructured":"Kumar SK, et al. Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;21(12):1281\u2013301. https:\/\/doi.org\/10.6004\/jnccn.2023.0061.","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"681_CR2","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1053\/j.seminhematol.2025.11.003","volume":"62","author":"JH Yi","year":"2025","unstructured":"Yi JH, Yoon DH, Kim K. Targeting B-cell maturation antigen in relapsed or refractory multiple myeloma: on the verge of its prime time. Semin Hematol. 2025;62(4):305\u201318. https:\/\/doi.org\/10.1053\/j.seminhematol.2025.11.003.","journal-title":"Semin Hematol"},{"key":"681_CR3","doi-asserted-by":"publisher","first-page":"6908","DOI":"10.1182\/blood-2024-198949","volume":"144","author":"J Cui","year":"2024","unstructured":"Cui J, Shen D, Liu G, Qiu L-G, An G. Real-world patient characteristics and outcomes in China multiple myeloma patients with unmet needs. Blood. 2024;144:6908. https:\/\/doi.org\/10.1182\/blood-2024-198949.","journal-title":"Blood"},{"key":"681_CR4","doi-asserted-by":"publisher","first-page":"6917","DOI":"10.1182\/blood-2024-201167","volume":"144","author":"J Xu","year":"2024","unstructured":"Xu J, et al. Analysis of diagnosis and treatment pattern for newly diagnosed multiple myeloma in China over 20 years. Blood. 2024;144:6917. https:\/\/doi.org\/10.1182\/blood-2024-201167.","journal-title":"Blood"},{"issue":"8","key":"681_CR5","doi-asserted-by":"publisher","first-page":"9604","DOI":"10.1002\/cam4.5737","volume":"12","author":"Y Yang","year":"2023","unstructured":"Yang Y, et al. The evolving diagnosis and treatment paradigms of multiple myeloma in China: 15 years\u2019 experience of 1256 patients in a national medical center. Cancer Med. 2023;12(8):9604\u201314. https:\/\/doi.org\/10.1002\/cam4.5737.","journal-title":"Cancer Med"},{"issue":"1","key":"681_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-025-22240-2","volume":"25","author":"X Diao","year":"1990","unstructured":"Diao X, Ben T, Cheng S, Niu S, Gao L, Xia N. Global, regional, and national multiple myeloma burden from 1990 to 2021: a systematic analysis for of the Global Burden of Disease Study 2021. BMC Public Health. 1990;25(1):1054. https:\/\/doi.org\/10.1186\/s12889-025-22240-2.","journal-title":"BMC Public Health"},{"issue":"3","key":"681_CR7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2022","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2022;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"Supplement 1","key":"681_CR8","doi-asserted-by":"publisher","first-page":"6710","DOI":"10.1182\/blood-2023-182729","volume":"142","author":"G An","year":"2023","unstructured":"An G, Li L, Liu S, Qiu L. Treatment patterns and outcomes in patients with multiple myeloma who received ixazomib and in patients with triple-class refractory multiple myeloma: a retrospective, observational, real-world historical database analysis study from China. Blood. 2023;142(Supplement 1):6710\u20136710. https:\/\/doi.org\/10.1182\/blood-2023-182729.","journal-title":"Blood"},{"issue":"5","key":"681_CR9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.6004\/jnccn.2025.0023","volume":"23","author":"SK Kumar","year":"2025","unstructured":"Kumar SK, et al. NCCN Guidelines\u00ae insights: multiple myeloma, version 1.2025. J Natl Compr Canc Netw. 2025;23(5):132\u201340. https:\/\/doi.org\/10.6004\/jnccn.2025.0023. (in Eng).","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"681_CR10","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1182\/blood-2019-131264","volume":"134","author":"RK Dao Tran","year":"2019","unstructured":"Dao Tran RK, Manthena S, Karve S. Economic burden of multiple myeloma: results from a large employer-sponsored real-world administrative claims database, 2012 to 2018. Blood. 2019;134(1):3414. https:\/\/doi.org\/10.1182\/blood-2019-131264.","journal-title":"Blood"},{"issue":"15_suppl","key":"681_CR11","doi-asserted-by":"publisher","first-page":"8060","DOI":"10.1200\/JCO.2016.34.15_suppl.8060","volume":"34","author":"M Hagiwara","year":"2016","unstructured":"Hagiwara M, Panjabi S, Sharma A, Chen YJ, Delea TE. Retrospective study of frequency and cost of multiple myeloma (MM) complications and treatment (Tx) related adverse events (AEs). J Clin Oncol. 2016;34(15_suppl):8060\u20138060. https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.8060.","journal-title":"J Clin Oncol"},{"issue":"1","key":"681_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1634\/theoncologist.2012-0113","volume":"18","author":"A Teitelbaum","year":"2013","unstructured":"Teitelbaum A, Ba-Mancini A, Huang H, Henk HJ. Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data. Oncologist. 2013;18(1):37\u201345. https:\/\/doi.org\/10.1634\/theoncologist.2012-0113.","journal-title":"Oncologist"},{"issue":"1","key":"681_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/10428194.2019.1648802","volume":"61","author":"M Hagiwara","year":"2020","unstructured":"Hagiwara M, Panjabi S, Delea T, Yucel E, Fonseca R. Burden of disease progression in patients with multiple myeloma in the US. Leuk Lymphoma. 2020;61(1):47\u201355. https:\/\/doi.org\/10.1080\/10428194.2019.1648802.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"681_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-13925-3","volume":"25","author":"L Wang","year":"2025","unstructured":"Wang L, et al. Real-world analysis of treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with newly diagnosed or relapsed\/refractory multiple myeloma. BMC Cancer. 2025;25(1):836. https:\/\/doi.org\/10.1186\/s12885-025-13925-3.","journal-title":"BMC Cancer"},{"issue":"12","key":"681_CR15","first-page":"1186","volume":"63","author":"C. S. o. H. Chinese Hematology Association","year":"2024","unstructured":"C. S. o. H. Chinese Hematology Association. Guidelines for the diagnosis and management of multiple myeloma in China (2024 revision). Chin J Intern Med. 2024;63(12):1186\u201395.","journal-title":"Chin J Intern Med"},{"issue":"8","key":"681_CR16","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/S1470-2045(25)00330-4","volume":"26","author":"V Hungria","year":"2025","unstructured":"Hungria V, et al. Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial. Lancet Oncol. 2025;26(8):1067\u201380. https:\/\/doi.org\/10.1016\/S1470-2045(25)00330-4.","journal-title":"Lancet Oncol"},{"issue":"5","key":"681_CR17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa2405090","volume":"391","author":"V Hungria","year":"2024","unstructured":"Hungria V, et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391(5):393\u2013407. https:\/\/doi.org\/10.1056\/NEJMoa2405090.","journal-title":"N Engl J Med"},{"key":"681_CR18","unstructured":"Drugs.com. Darzalex Faspro prices, coupons, copay cards & patient assistance. Drugs.com. https:\/\/www.drugs.com\/price-guide\/darzalex-faspro. Accessed 27 May 2026."},{"key":"681_CR19","unstructured":"GSK. Wholesale acquisition cost for BLENREP. GlaxoSmithKline. https:\/\/www.togetherwithgsk.com\/content\/dam\/brs-pharma-us\/togetherwithgsk-v2\/en_US\/blenrep\/pdfs\/hcp\/wholesale-acquisition-cost-blenrep.pdf. Accessed 27 May 2026."},{"issue":"1","key":"681_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharp.2026.03.003","volume":"2","author":"J Wu","year":"2026","unstructured":"Wu J, Liu GG. Comments on the 2025 edition of China guidelines for pharmacoeconomic evaluations. Pharmacoecon Policy. 2026;2(1):1\u20133. https:\/\/doi.org\/10.1016\/j.pharp.2026.03.003.","journal-title":"Pharmacoecon Policy"},{"key":"681_CR21","volume-title":"China guidelines for pharmacoeconomic evaluations (2025 Bilingual Edition)","author":"GGLJ Wu","year":"2025","unstructured":"Wu GGLJ. China guidelines for pharmacoeconomic evaluations (2025 Bilingual Edition). China Planning Press; 2025."},{"key":"681_CR22","unstructured":"China Data Portal. China GDP per capita. 2026. https:\/\/chinadata.live\/data\/china-gdp-per-capita\/."},{"issue":"1","key":"681_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3\u20139. https:\/\/doi.org\/10.1016\/j.jval.2021.11.1351.","journal-title":"Value Health"},{"issue":"8","key":"681_CR24","doi-asserted-by":"publisher","first-page":"e599","DOI":"10.1016\/S2352-3026(25)00163-2","volume":"12","author":"V Hungria","year":"2025","unstructured":"Hungria V, et al. Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial. Lancet Haematol. 2025;12(8):e599\u2013610. https:\/\/doi.org\/10.1016\/S2352-3026(25)00163-2.","journal-title":"Lancet Haematol"},{"key":"681_CR25","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.2147\/rmhp.S475048","volume":"17","author":"L Yi","year":"2024","unstructured":"Yi L, et al. Economic evaluation of adding daratumumab to carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Risk Manag Healthc Policy. 2024;17:2829\u201337. https:\/\/doi.org\/10.2147\/rmhp.S475048.","journal-title":"Risk Manag Healthc Policy"},{"issue":"1","key":"681_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13561-025-00611-0","volume":"15","author":"W Wu","year":"2025","unstructured":"Wu W, et al. Cost-effectiveness analysis of combination therapies involving novel agents for first\/second-relapse patients with multiple myeloma: a Markov model approach with calibration techniques. Health Econ Rev. 2025;15(1):21. https:\/\/doi.org\/10.1186\/s13561-025-00611-0.","journal-title":"Health Econ Rev"},{"issue":"1","key":"681_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJNM, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1):9. https:\/\/doi.org\/10.1186\/1471-2288-12-9.","journal-title":"BMC Med Res Methodol"},{"key":"681_CR28","unstructured":"D. o. E. a. S. A. United Nations, Population Division. World population prospects 2024. 2024. Online edition."},{"issue":"6","key":"681_CR29","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1177\/0272989x231184247","volume":"43","author":"MJ Sweeting","year":"2023","unstructured":"Sweeting MJ, et al. Survival extrapolation incorporating general population mortality using excess hazard and cure models: a tutorial. Med Decis Making. 2023;43(6):737\u201348. https:\/\/doi.org\/10.1177\/0272989x231184247. (in Eng).","journal-title":"Med Decis Making"},{"issue":"2","key":"681_CR30","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.clinthera.2019.12.007","volume":"42","author":"X Zeng","year":"2020","unstructured":"Zeng X, Peng L, Peng Y, Tan C, Wan X. Economic evaluation of adding Daratumumab to a regimen of Bortezomib + Dexamethasone in relapsed or refractory multiple myeloma: based on the latest updated analysis of CASTOR. Clin Ther. 2020;42(2):251-262.e5. https:\/\/doi.org\/10.1016\/j.clinthera.2019.12.007.","journal-title":"Clin Ther"},{"issue":"1","key":"681_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-97259-7","volume":"11","author":"SE Congly","year":"2021","unstructured":"Congly SE, Varughese RA, Brown CE, Clement FM, Saxinger L. Treatment of moderate to severe respiratory COVID-19: a cost-utility analysis. Sci Rep. 2021;11(1):17787. https:\/\/doi.org\/10.1038\/s41598-021-97259-7.","journal-title":"Sci Rep"},{"issue":"4","key":"681_CR32","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.cjtee.2018.05.001","volume":"21","author":"Y-X Su","year":"2018","unstructured":"Su Y-X, Xu L, Gao X-J, Wang Z-Y, Lu X, Yin C-F. Long-term quality of life after sepsis and predictors of quality of life in survivors with sepsis. Chin J Traumatol Zhonghua chuang shang za zhi. 2018;21(4):216\u201323. https:\/\/doi.org\/10.1016\/j.cjtee.2018.05.001.","journal-title":"Chin J Traumatol Zhonghua chuang shang za zhi"},{"issue":"2","key":"681_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/cc8957","volume":"14","author":"R Linko","year":"2010","unstructured":"Linko R, et al. One-year mortality, quality of life and predicted life-time cost-utility in critically ill patients with acute respiratory failure. Crit Care. 2010;14(2):R60. https:\/\/doi.org\/10.1186\/cc8957.","journal-title":"Crit Care"},{"key":"681_CR34","doi-asserted-by":"publisher","first-page":"S362","DOI":"10.1016\/j.jval.2019.04.1770","volume":"22","author":"Y Huang","year":"2019","unstructured":"Huang Y, Wang C, Xue X, Wu G, Li J. PRS66 a cost analysis of current situation of pneumonia treatment in China: a big-data hospital information system (HIS) database analysis. Value Health. 2019;22:S362. https:\/\/doi.org\/10.1016\/j.jval.2019.04.1770.","journal-title":"Value Health"},{"key":"681_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1066694","author":"S Yuan","year":"2020","unstructured":"Yuan S, Li T, Chu C, Wang X, Liu L. Treatment cost assessment for COVID-19 inpatients in Shenzhen, China 2020\u20132021: facts and suggestions. Front Public Health. 2020. https:\/\/doi.org\/10.3389\/fpubh.2023.1066694.","journal-title":"Front Public Health"},{"issue":"1","key":"681_CR36","doi-asserted-by":"publisher","first-page":"12679","DOI":"10.1038\/s41598-025-97591-2","volume":"15","author":"K Zhu","year":"2025","unstructured":"Zhu K, Pan Z, Qin M, Huang J. The cost effectiveness of penpulimab with paclitaxel and carboplatin in first-line treatment of metastatic squamous non-small cell lung cancer. Sci Rep. 2025;15(1):12679. https:\/\/doi.org\/10.1038\/s41598-025-97591-2.","journal-title":"Sci Rep"},{"issue":"12","key":"681_CR37","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3109\/00365548.2013.827338","volume":"45","author":"S-P Jiang","year":"2013","unstructured":"Jiang S-P, Zhu Z-Y, Ma K-F, Zheng X, Lu X-Y. Impact of pharmacist antimicrobial dosing adjustments in septic patients on continuous renal replacement therapy in an intensive care unit. Scand J Infect Dis. 2013;45(12):891\u20139. https:\/\/doi.org\/10.3109\/00365548.2013.827338.","journal-title":"Scand J Infect Dis"},{"issue":"4","key":"681_CR38","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jiph.2017.10.003","volume":"11","author":"T Yan","year":"2018","unstructured":"Yan T, et al. Hospital-acquired lower respiratory tract infections among high risk hospitalized patients in a tertiary care teaching hospital in China: an economic burden analysis. J Infect Public Health. 2018;11(4):507\u201313. https:\/\/doi.org\/10.1016\/j.jiph.2017.10.003.","journal-title":"J Infect Public Health"},{"issue":"3","key":"681_CR39","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.chest.2021.08.057","volume":"161","author":"PE Boucher","year":"2022","unstructured":"Boucher PE, Taplin J, Clement F. The cost of ARDS: a systematic review. Chest. 2022;161(3):684\u201396. https:\/\/doi.org\/10.1016\/j.chest.2021.08.057.","journal-title":"Chest"},{"key":"681_CR40","doi-asserted-by":"publisher","first-page":"108533","DOI":"10.1016\/j.lungcan.2025.108533","volume":"203","author":"Q Wu","year":"2025","unstructured":"Wu Q, Li Q, Qin Y. A cost-effectiveness analysis of amivantamab plus lazertinib versus osimertinib in the treatment of US and Chinese patients with EGFR-mutated advanced non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 2025;203:108533. https:\/\/doi.org\/10.1016\/j.lungcan.2025.108533.","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"11","key":"681_CR41","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/j.jval.2024.06.020","volume":"27","author":"GG Liu","year":"2024","unstructured":"Liu GG, et al. Key issues of economic evaluations for health technology assessment in China: a nationwide expert survey. Value Health. 2024;27(11):1535\u201343. https:\/\/doi.org\/10.1016\/j.jval.2024.06.020.","journal-title":"Value Health"},{"issue":"9","key":"681_CR42","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.jval.2021.03.008","volume":"24","author":"I van Oostrum","year":"2021","unstructured":"van Oostrum I, et al. Comparison of parametric survival extrapolation approaches incorporating general population mortality for adequate health technology assessment of new oncology drugs. Value Health. 2021;24(9):1294\u2013301. https:\/\/doi.org\/10.1016\/j.jval.2021.03.008. (in Eng).","journal-title":"Value Health"},{"key":"681_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.08.017","author":"A Zayad","year":"2025","unstructured":"Zayad A, et al. Efficacy and safety of daratumumab, pomalidomide and dexamethasone compared to daratumumab, carfilzomib and dexamethasone in relapsed multiple myeloma: multicenter real-world experience. Clin Lymphoma Myeloma Leuk. 2025. https:\/\/doi.org\/10.1016\/j.clml.2025.08.017.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"681_CR44","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.clml.2022.10.007","volume":"23","author":"W Fu","year":"2023","unstructured":"Fu W, et al. Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: updated analysis of LEPUS. Clin Lymphoma Myeloma Leuk. 2023;23(1):e51\u20138. https:\/\/doi.org\/10.1016\/j.clml.2022.10.007. (in Eng).","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"681_CR45","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-025-02753-x","volume":"42","author":"R Amin","year":"2025","unstructured":"Amin R, Dey BK, Darwin R, Cho WC, Sharifi-Rad J, Calina D. BCMA-targeted therapies in multiple myeloma: advances, challenges and future prospects. Med Oncol. 2025;42(6):204. https:\/\/doi.org\/10.1007\/s12032-025-02753-x. ((in eng)).","journal-title":"Med Oncol"},{"issue":"12","key":"681_CR46","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1080\/17474086.2021.1970522","volume":"14","author":"A Nikolaou","year":"2021","unstructured":"Nikolaou A, et al. Belantamab mafodotin for the treatment of relapsed\/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis. Expert Rev Hematol. 2021;14(12):1137\u201345. https:\/\/doi.org\/10.1080\/17474086.2021.1970522. ((in eng)).","journal-title":"Expert Rev Hematol"},{"key":"681_CR47","unstructured":"Belantamab mafodotin (Blenrep), dexamethasone: Indication: Belantamab mafodotin is indicated in combination with bortezomib and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy. Canadian Agency for Drugs and Technologies in Health, October 2025 (in Eng)."}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00681-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-026-00681-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00681-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T06:23:09Z","timestamp":1789107789000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-026-00681-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":47,"alternative-id":["681"],"URL":"https:\/\/doi.org\/10.1007\/s41669-026-00681-8","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"3 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data supporting the findings of this study are available within the paper. The codes for all the analyses are available from the corresponding author upon reasonable request.","order":4,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to the study conception and design. Xiaotong Zhang and Xiaoxuan Xing contributed equally to this article through the concept and planning of the work described, drafting and critical revision of the manuscript. Ke Wang, Zhizhou Wang and Yiming Hua contributed to the acquisition, analysis and interpretation of the data. Xianzhe Dong and Lan Zhang provided supervision and project administration. All authors reviewed and approved the final submitted version of the manuscript.","order":5,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}